| Literature DB >> 15716361 |
Francesco Fornai1, Oliver M Schlüter, Paola Lenzi, Marco Gesi, Riccardo Ruffoli, Michela Ferrucci, Gloria Lazzeri, Carla L Busceti, Fabrizio Pontarelli, Giuseppe Battaglia, Antonio Pellegrini, Ferdinando Nicoletti, Stefano Ruggieri, Antonio Paparelli, Thomas C Südhof.
Abstract
In animals, sporadic injections of the mitochondrial toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) selectively damage dopaminergic neurons but do not fully reproduce the features of human Parkinson's disease. We have now developed a mouse Parkinson's disease model that is based on continuous MPTP administration with an osmotic minipump and mimics many features of the human disease. Although both sporadic and continuous MPTP administration led to severe striatal dopamine depletion and nigral cell loss, we find that only continuous administration of MPTP produced progressive behavioral changes and triggered formation of nigral inclusions immunoreactive for ubiquitin and alpha-synuclein. Moreover, only continuous MPTP infusions caused long-lasting activation of glucose uptake and inhibition of the ubiquitin-proteasome system. In mice lacking alpha-synuclein, continuous MPTP delivery still induced metabolic activation, but induction of behavioral symptoms and neuronal cell death were almost completely alleviated. Furthermore, the inhibition of the ubiquitinproteasome system and the production of inclusion bodies were reduced. These data suggest that continuous low-level exposure of mice to MPTP causes a Parkinson-like syndrome in an alpha-synuclein-dependent manner.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15716361 PMCID: PMC552938 DOI: 10.1073/pnas.0409713102
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205